TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
AMRX

Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

20.30$ +1.1% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Amneal Pharmaceuticals, Inc. (AMRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 3,776 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet AMRX
Line item Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
1,219 1,219 1,219 1,240 1,342 1,359 4,545 4,582 4,353 4,385 4,262 3,704 3,666 4,391 4,057 4,038 4,006 3,960 4,023 3,974 3,940 3,889 4,041 3,874 3,799 3,627 3,701 3,687 3,473 3,456 3,510 3,461 3,501 3,365 3,423 3,600 3,678 3,540 3,776
726 32 – 694 772 48 1,348 1,431 1,287 1,268 1,186 1,206 1,210 1,774 1,481 1,544 1,552 1,560 1,563 1,570 1,520 1,390 1,554 1,420 1,412 1,307 1,422 1,456 1,378 1,380 1,485 1,513 1,588 1,510 1,585 1,838 1,911 1,798 1,947
27 -32 – 19 74 48 62 165 213 64 55 213 151 405 266 281 341 452 278 303 248 210 92 87 26 145 109 87 92 48 44 74 111 59 81 201 311 198 128
32 32 – 19 74 48 62 165 213 64 55 213 152 405 266 281 343 452 280 305 249 212 94 90 28 148 113 92 94 48 47 74 112 59 81 201 311 198 128
407 – – 340 351 349 646 659 565 640 635 518 604 763 583 743 639 531 652 628 663 538 689 629 742 546 675 691 646 704 803 786 776 800 849 924 940 903 1,021
266 – – 278 284 328 512 491 457 448 415 402 381 438 444 476 491 497 523 520 489 512 533 544 531 529 551 576 581 571 576 596 612 601 609 615 606 642 678
407 – – – 487 490 569 567 544 658 648 627 621 611 606 462 478 471 598 460 514 501 603 587 470 463 459 – – – – – – – – – – – –
28 – – 26 26 26 386 411 426 422 420 420 420 515 527 523 523 523 549 566 593 603 601 600 599 599 599 599 599 599 599 598 597 597 597 596 595 594 593
46 – – 45 45 48 1,789 1,733 1,655 1,591 1,553 1,436 1,383 1,475 1,424 1,349 1,305 1,263 1,293 1,233 1,167 1,210 1,204 1,159 1,096 1,055 1,015 983 890 859 820 780 732 689 650 588 563 535 588
1,395 – – 1,666 1,717 1,728 3,605 3,667 3,456 3,585 3,513 3,308 3,319 3,987 3,686 3,689 3,649 3,593 3,619 3,576 3,556 3,465 3,851 3,657 3,590 3,464 3,518 3,496 3,411 3,473 3,514 3,495 3,546 3,425 3,470 3,710 3,672 3,586 3,659
225 – – 259 297 313 670 749 554 600 546 535 550 965 655 668 677 637 673 667 677 602 993 818 753 704 777 761 847 834 1,114 1,095 1,130 1,076 1,107 862 882 728 883
1,197 1,197 – 65 89 89 99 200 22 38 38 38 37 347 47 46 57 42 44 45 46 46 131 107 105 145 166 123 228 229 452 381 340 338 335 21 22 21 121
60 – – 67 70 84 169 125 115 546 503 496 103 594 602 618 154 581 598 591 133 542 564 533 167 137 140 177 144 175 200 235 260 193 667 266 255 228 244
1,160 – – – 1,395 1,392 2,641 2,675 2,631 2,625 2,620 2,614 2,609 2,807 2,800 2,757 2,735 2,728 2,757 2,688 2,680 2,673 2,661 2,607 2,592 2,602 2,590 2,583 2,427 2,420 2,178 2,170 2,162 2,154 2,146 2,567 2,565 2,566 2,564
-185 -185 – -437 -386 0.0 495 501 896 472 460 396 232 318 306 301 303 323 346 351 360 391 280 297 298 294 318 331 20 -64 -57 -93 -109 -132 -113 -109 -71 -45 33
-175 – – -424 -383 -358 -19 -12 -21 -64 -81 -346 -378 -263 -275 -284 -287 -280 -266 -270 -276 -278 -399 -402 -406 -413 -401 -392 -490 -582 -576 -576 -607 -595 -572 -570 -535 -473 -415
115 115 115 115 115 115 127 128 127 128 128 131 142 148 147 148 148 151 152 149 149 150 151 151 151 152 155 160 244 307 319 310 310 324 322 325 325 329 328

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?